Effect of Trimetazidine on clinical events after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction.

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ANZCTR

Registry ID

ACTRN12619001616167

Enrollment

680

Registered

2019-11-22

Start date

2016-01-01

Completion date

2016-04-01

Last updated

2019-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

Trimetazidine (TMZ) is considered by most researchers as an anti-ischemic agent with anti-oxidant activity. The aim of this multicenter prospective study is to evaluate the long-term (6-month) effect of TMZ on post-discharge outcomes after primary percutaneous coronary intervention (PCI) in patients with primary ST-elevation myocardial infarction (STEMI).We compared left ventricular ejection fraction (LVEF) and cardiac readmission rates including those of recurrent ischemia due to restenosis in the TMZ and control groups at the end of 3 rd and 6 th months.

Interventions

Trimetazidine 35 mg oral tablet, twice per day, 6 month Every two out of three STEMI patients received medication. Every third patient on a medical attendance list was not offered to receiving medication ''Trimetazidine", thus the ratio of patients in groups is approximately 2: 1

Study design

Allocation

Non-randomised trial

Intervention model

Parallel

Primary purpose

Treatment

Masking

Open (masking not used)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

ST-elevation myocardial infarction

Exclusion criteria

previous or recurrent acute myocardial infarction, heart valve disease, acute cerebrovascular or vessel disease, serious renal or live failure, oncologic disease or any other non-cardiologic serious medical condition with a life expectancy of less than 1 year,

Outcome results